摘要
重症肺炎是不同病因或病原菌所导致的肺组织炎症恶化发展到一定阶段的严重疾病状态,其发病凶险,如不及时有效救治,可能危及生命。莫西沙星作为第四代氟喹诺酮类抗菌药物,具有高效、广谱、耐药率低、药物相互作用少等优点,常被用于呼吸系统感染的救治。但对于重症肺炎,莫西沙星单药治疗可能无法完成满足临床的救治需求,故常会与其他抗菌药物、非抗菌药物和非药物治疗联用,以达到有效治疗的目的。该文通过对莫西沙星与其他抗菌药物、非抗菌药物和非药物治疗联用治疗重症肺炎进行综述和分析,以期为临床重症肺炎的有效治疗提供参考。
Severe pneumonia is a critical disease state resulting from the progressive deterioration of lung tissue inflammation induced by various etiologies or pathogenic bacteria.It has an acute onset,and may be life-threatening without timely and effective treatment.As a fourth-generation fluoroquinolone antibacterial drug,moxifloxacin possesses advantages such as high efficacy,broad-spectrum activity,low drug resistance rate,and few drug-drug interactions,making it widely used in the treatment of respiratory system infections.However,monotherapy with moxifloxacin may not fully meet the clinical treatment needs of severe pneumonia.Therefore,it is often combined with other antibacterial drugs,non-antibacterial drugs,and non-pharmacological treatments to achieve effective treatment outcomes.This article reviews and analyzes the combined use of moxifloxacin with other antibacterial drugs,non-antibacterial drugs,and non-pharmacological treatments for severe pneumonia,aiming to provide a reference for the effective clinical treatment of severe pneumonia.
作者
王燕飞
刘志
WANG Yan-fei;LIU Zhi(Hospital of the 63710 Unit of the Chinese People's Liberation Army,Xinzhou Shanxi 036300,China)
出处
《抗感染药学》
2025年第6期538-542,共5页
Anti-infection Pharmacy
关键词
莫西沙星
重症肺炎
联合治疗
moxifloxacin
severe pneumonia
combined therapy
